PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
By J. S. Suk, Qingguo Xu, Namho Kim, J. Hanes, L. Ensign. Advanced Drug Delivery Reviews, 2015
3,831 citations recorded by the source corpus.
Coating the surface of nanoparticles with polyethylene glycol (PEG), or “PEGylation”, is a commonly used approach for improving the efficiency of drug and gene delivery to target cells and tissues. Building from the success of PEGylating proteins to improve systemic circulation time and decrease immunogenicity, the impact of PEG coatings on the fate of systemically administered nanoparticle formulations has, and continues to be, widely studied. PEG coatings on nanoparticles shield the surface from aggregation, opsonization, and phagocytosis, prolonging systemic circulation time. Here, we briefly describe the history of the development of PEGylated nanoparticle formulations for systemic administration, including how factors such as PEG molecular weight, PEG surface density, nanoparticle core properties, and repeated administration impact circulation time. A less frequently discussed topic, we then describe how PEG coatings on nanoparticles have also been utilized for overcoming various biological barriers to efficient drug and gene delivery associated with other modes of administration, ranging from gastrointestinal to ocular. Finally, we describe both methods for PEGylating nanoparticles and methods for characterizing PEG surface density, a key factor in the effectiveness of the PEG surface coating for improving drug and gene delivery.
Subfields: Biomaterials, Molecular Biology, Pharmaceutical Science
View Paper: https://www.semanticscholar.org/paper/6a5e6c90712d8933aa81b1fabe6d1709d9e1c4e4
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biomaterials
In Molecular Biology
In Pharmaceutical Science
Citations in the corpus
- Nanoparticles in the clinic (2016, background): “Interestingly, recent preclinical work has highlighted advantages of PEGylated particles beyond extended circulation, notably their diffusion in tissues(118) and their abilities to pass through tight biological barriers.(36,119) It is possible that clinically used PEGylated particles have benefitted”
- Chitosan Derivatives and Their Application in Biomedicine (2020, background): “For example, methoxy polyethylene glycol-modified trimethyl chitosan (mPEG-TMC) has been covalently linked to doxorubicin (DOX) and cis-itaconic anhydride (CA) in order to give mPEG-TCD NPs, where anti-tumor effects have shown that the mPEG-TCD NPs exhibit better anti-tumor activities when compared ”
- Liposomes: structure, composition, types, and clinical applications (2022, background): “Decorating the surface of these liposomes with poly ethylene glycol (PEG) protects the them from the circulating proteins, improving the drug efficiency through improving systemic circulation time and decrease immunogenicity [91, 92].”
- The delivery of therapeutic oligonucleotides (2016, background): “However, this has been only partially successful despite many attempts to modify nanoparticle surfaces with polyethylene glycol (PEG) or other inert polymers (55,56).”